Navigation Links
Gauze-based NPWT Capable of Achieving Same Treatment Goals as Foam-based NPWT

ST. PETERSBURG, Fla., Oct. 23 /PRNewswire-FirstCall/ -- The Advanced Wound Management Division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew Plc (LSE: SN; NYSE: SNN), highlighted the results of a multi-center study which demonstrates that gauze-based Negative Pressure Wound Therapy (NPWT) achieves many of the common treatment goals defined for foam-based NPWT systems. These goals include a reduction in wound dimension, exudate, and improvement in granulation tissue. A second poster highlighting a sub-set of patients in the same study found that skin graft take was dramatically enhanced and care facilitated by gauze-based NPWT.

The results of this study were presented in a poster session today at the 24th Annual Clinical Symposium on Advances in Skin and Wound Care in San Antonio, Texas.

The prospective, multi-center clinical evaluation assessed 131 non-grafted patients at 21 centers in the United States, Canada, United Kingdom, Saudi Arabia and the United Arab Emirates. Its results included:

  • Wound dimensions were all significantly reduced during gauze-based NPWT (p<0.001). A weekly percentage reduction in wound area, depth and volume of 8.3%, 15.8% and 20.5% respectively was observed;
  • There was a significant reduction (p<0.001) in wound exudate levels from baseline to treatment discontinuation;
  • There was also a significant increase (p=0.007) in the percentage area of the wound bed composed of red granulation tissue over the course of gauze-based NPWT.

"Gauze-based NPWT can be used to address many of the treatment goals commonly defined at the onset of applying other NPWT systems," said Dr. Raymond Dunn, Chairman of Plastic Surgery, University of Massachusetts and lead author of the poster. "Clinicians in this study found the gauze-based negative pressure system to be versatile and capable of application to a wide variety of wounds that due to their location, extent and level of exudate would be difficult to manage with foam dressings. The gauze filler used in this evaluation also demonstrated some positive advantages regarding its conformability and ease of application to large and irregular wounds."

The second poster in today's session presented results from a sub-set of 23 grafted patients with split-thickness skin grafts (STSG) that were treated with gauze-based NPWT post-operatively. The average STSG percentage take was 83%, with an average percentage take for diabetics of 50% and for non-diabetics of 95%. There were no complaints of major discomfort and no significant infections. The study validates NPWT's ability to immobilize a graft, which has several positive advantages that improve overall graft survival.

"These exciting studies provide the efficacy data needed to demonstrate that both gauze and foam interfaces provide comparable healing rates in NPWT systems," said Patricia Burns, RN, MSN, CWOCN, Senior Director of Clinical Affairs, Smith & Nephew Advanced Wound Management. "This is an important contribution to the body of science underscoring the value of having options when applying NPWT. Based on the individual needs of the patient, clinicians can choose between gauze and foam wound interfaces with confidence that either approach will meet their clinical objectives for NPWT."

Both posters are available at The Symposium continues through Sunday, October 25 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Smith & Nephew is Booth # 111.

For more information about Smith & Nephew's complete RENASYS(TM) line of NPWT products, please visit, and regarding Smith & Nephew, please visit

About Smith & Nephew

Smith & Nephew is a global medical technology business, specializing in Orthopeadics, including Reconstruction, Trauma and Clinical Therapies, Endoscopy and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopeadics companies.

Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2008 were nearly $3.8 billion.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

SOURCE Smith & Nephew Inc.

SOURCE Smith & Nephew Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
2. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
3. CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
Post Your Comments:
(Date:11/26/2015)... , November 27, 2015 /PRNewswire/ ... --> Medical ... response system (PERS) market is ... 5 years with APAC being ... to see a high CAGR ...
(Date:11/26/2015)... --> --> ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... with Bremachlorin-photodynamic therapy for advanced cancer.   ... with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy can be efficiently combined with photodynamic therapy (PDT) ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and Markets ( ... Pacific Cardiac Pacemaker Market Outlook to 2019 - Rise in ... Demand " report to their offering. ... Boston scientific and others. ... including Medtronic, Biotronik, Boston scientific and ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to ... Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored ... one of twelve colleges and universities in the state of California make the cut. ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients ... central Michigan, have come together on Thanksgiving Day to share the things that ... viewing on the Serenity Point YouTube channel, patients displayed what they wrote on ...
(Date:11/26/2015)... ... ... Jobs in hospital medical laboratories and in the imaging field lead the ... Aureus Medical Group . These fields, as well as travel nursing, ranked ... jobs through the company’s website, , The leading healthcare staffing agency ...
(Date:11/26/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact center ... reliability. , The new Q-Suite 6 platform is based on the latest Java Enterprise ... a specific piece of software for many key components of the suite. Much of ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... recognized once again for its stellar workplace culture with the company’s Cincinnati office ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati Business Courier’s ...
Breaking Medicine News(10 mins):